NCT02632526 - A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 10, 2016

Primary Completion Date

August 26, 2016

Study Completion Date

August 26, 2016

Conditions

Healthy Male SubjectsCardiovascular Disease

Interventions

DRUG

AZD5718 oral suspension crystalline form (1 to 100 mg/mL) (Part A)

Oral suspension single dose

DRUG

AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A)

Single and multiple doses

DRUG

AZD5718 placebo oral suspension

Single and multiple doses

DRUG

AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part B)

Single and multiple doses

Trial Locations (1)

Research Site, Harrow